EDS ECHO Summit Series: Classical Ehlers-Danlos Syndrome (cEDS)
April 2-3, 2022
We are delighted to be hosting a dedicated event focusing on classical Ehlers-Danlos syndrome (cEDS). Join us as leading experts present the latest research, management, and scientific information, featuring presentations on the following topics:
- Pain Management
- Physical Therapy
- Genetic Counseling
- ECM, Fibroblasts, and Wound Healing
- Research Approaches in Rare Diseases
- Multisystem Manifestations
This two-day event is suitable for both healthcare professionals, and members of the EDS and HSD community, their families, and caregivers. April 2 will be Healthcare Professionals Day, and April 3 will be Community Day; both event days will take place from 08:30 AM – 4:00 PM Eastern Time. (Please use the converter world time buddy to find the correct times in your location)
11 CME/CEU/CE credits will be available for healthcare professionals to claim for sessions that are viewed LIVE.
The event will take place online via Zoom Webinar. If you have questions please email email@example.com.
In support of improving patient care, this activity has been planned and implemented by the Ehlers-Danlos Society and Project ECHO. Project ECHO® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Designation Statement
Project ECHO® designates this live activity for a maximum of 11 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Project ECHO®, in compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, requires that anyone who is in a position to control the content of an educational activity disclose all relevant financial relationships they have had within the last 24 months with an ineligible company.
None of the planners and presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Prof. Lara Bloom, Dr. Alan Hakim, Dr. Clair Francomano, Dr. Keren Machol, Prof. Fransiska Malfait Stacey Simmonds, Sacha Aziz, Dr. Jane Schubart, Dr. Christina Laukaitis, Dr. Brendan Lee, Dr. Jason Lim, Dr. Nigel Burrows, Alyssa Graybeal, Dr. Katja Kovacic, Dr. Alex Levin, Dr. Helen Cohen, Jessica Bowen, Dr. Natalie Blagowidow, Dr. Delfien Syx, Dr. Marlies Colman, Dr. Michael Healy, and Tiffany Vincent.
The following planners/presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company.
|Nature of Relationship||Name of Ineligible Company|
|Dr. Anne-Marie Malfait||Grants/Research Support, Consultant||GSK, 23andMe, AKP, Ventus, Collegium Pharmaceuticals|
|Dr. Ann Beal Salamone||Grants/Research Support||Rochal Industries, Sanara MedTech Stockholder|
|Dr. Amy Kontorovich||Grants/Research Support||Akcea Therapeutics|
All of the relevant financial relationships listed for this/these individual(s) have been mitigated.